Financials
Financial year 2025
PATHOMATION from Antwerpen, company number BE0500694204, closed financial year 2025 with a result of € -402,294 after tax. For that financial year PATHOMATION recorded a gross margin of € 568,228 and equity of € 890,585. Compared with financial year 2024, the result moved from € 7,002 to € -402,294. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 890,585
▼ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -402,294
▼ still € 7,002 profit in 2024
Profit after tax over the fiscal year.
€ 109,401
▼ 88% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 665.
People and assets in 2025
7.4
▲ 2.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 617,444
▲ 51% vs 2024
€ 83,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 17,082
▲ € 16,069 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 116,181
▼ 45% vs 2024
€ 20,767 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 78,646
▼ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 66,481
▲ 21% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 445,114 | € 739,917 | € 684,218 | € 568,228 | ▼ 17% |
| Profit after taxes | € -125,164 | € 105,141 | € 7,002 | € -402,294 | ▼ € 409,296 |
| Equity | € 380,816 | € 485,957 | € 1,292,879 | € 890,585 | ▼ 31% |
| Total debts | € 537,401 | € 566,082 | € 1,355,539 | € 808,477 | ▼ 40% |
| Cash | € 30,552 | € 40,518 | € 912,228 | € 109,401 | ▼ 88% |
| Land & buildings | € 3,397 | - | - | - | |
| Retained profit | € 290,816 | € 395,957 | € 402,959 | € 665 | ▼ € 402,294 |
| Bank debt | € 158,773 | € 124,727 | € 211,383 | € 116,181 | ▼ 45% |
| Balance sheet total | € 918,216 | € 1,052,039 | € 2,648,418 | € 1,699,061 | ▼ 36% |
| Employees (FTE) | 4.8 | 4.9 | 5.2 | 7.4 | ▲ 2.2 |
Key figures of PATHOMATION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PATHOMATION?
What happened at PATHOMATION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 402,294 (▼ € 409,296 vs 2024). Source: NBB ↗
- Heitbrink Teixidor SL became a director. NBB
- CellCarta NV became a director. NBB
- Kockx-Consulting BV stepped down as director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 125,164 loss in 2022 to € 402,294 loss in 2025.
Paid € 10,766 in corporate taxes since 2022.
Best year ever: 2023, with € 105,141 profit.
On average € 76,800 of value added per employee in 2025.
A new publication or filing at PATHOMATION? We notify you, reason included.
Follow PATHOMATIONDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of CellCarta comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PATHOMATIONBehind PATHOMATION are Histodig BV, Heitbrink Teixidor SL and CellCarta NV. The shares are held by CellCarta (18.5%).
Directors
According to the 2025 annual accounts
Director · represented by Filip Heitbrink
since 2026
since 2026
Director · represented by Mark Kockx
Also active at: BATYO, CellCarta, HistoGeneX Holding, Arsenal IO Belgium
· until 2026
Shareholders
CellCarta · holding of CellCarta NV
18.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Prinses Joséphine Charlottelaan 10
2600 Antwerpen
Sint-Bavostraat 78-80
2610 Antwerpen
Active since 8 November 2012
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0500.694.204
- VAT number
- BE 0500.694.204
- Registered office
- Prinses Joséphine Charlottelaan 10, 2600 Antwerpen
- Names & denominations
- PATHOMATION
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 November 2012
- Peppol
- Active · Active since 4 Apr 2025
- Activities · NACE
Ontwerpen van computerprogramma’s
Ontwerpen en programmeren van computerprogramma's
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten